Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021–February 2022
dc.contributor.author | Kim, Sara S. | |
dc.contributor.author | Chung, Jessie R. | |
dc.contributor.author | Talbot, H. Keipp | |
dc.contributor.author | Grijalva, Carlos G. | |
dc.contributor.author | Wernli, Karen J. | |
dc.contributor.author | Kiniry, Erika | |
dc.contributor.author | Martin, Emily T. | |
dc.contributor.author | Monto, Arnold S. | |
dc.contributor.author | Belongia, Edward A. | |
dc.contributor.author | McLean, Huong Q. | |
dc.contributor.author | Gaglani, Manjusha | |
dc.contributor.author | Mamawala, Mufaddal | |
dc.contributor.author | Nowalk, Mary Patricia | |
dc.contributor.author | Moehling Geffel, Krissy | |
dc.contributor.author | Tartof, Sara Y. | |
dc.contributor.author | Florea, Ana | |
dc.contributor.author | Lee, Justin S. | |
dc.contributor.author | Tenforde, Mark W. | |
dc.contributor.author | Patel, Manish M. | |
dc.contributor.author | Flannery, Brendan | |
dc.contributor.author | Bentz, Meghan L. | |
dc.date.accessioned | 2022-11-09T21:19:05Z | |
dc.date.available | 2023-12-09 16:19:04 | en |
dc.date.available | 2022-11-09T21:19:05Z | |
dc.date.issued | 2022-11 | |
dc.identifier.citation | Kim, Sara S.; Chung, Jessie R.; Talbot, H. Keipp; Grijalva, Carlos G.; Wernli, Karen J.; Kiniry, Erika; Martin, Emily T.; Monto, Arnold S.; Belongia, Edward A.; McLean, Huong Q.; Gaglani, Manjusha; Mamawala, Mufaddal; Nowalk, Mary Patricia; Moehling Geffel, Krissy; Tartof, Sara Y.; Florea, Ana; Lee, Justin S.; Tenforde, Mark W.; Patel, Manish M.; Flannery, Brendan; Bentz, Meghan L. (2022). "Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021–February 2022." Influenza and Other Respiratory Viruses 16(6): 975-985. | |
dc.identifier.issn | 1750-2640 | |
dc.identifier.issn | 1750-2659 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/175107 | |
dc.description.abstract | BackgroundWe estimated SARS-CoV-2 Delta- and Omicron-specific effectiveness of two and three mRNA COVID-19 vaccine doses in adults against symptomatic illness in US outpatient settings.MethodsBetween October 1, 2021, and February 12, 2022, research staff consented and enrolled eligible participants who had fever, cough, or loss of taste or smell and sought outpatient medical care or clinical SARS-CoV-2 testing within 10 days of illness onset. Using the test-negative design, we compared the odds of receiving two or three mRNA COVID-19 vaccine doses among SARS-CoV-2 cases versus controls using logistic regression. Regression models were adjusted for study site, age, onset week, and prior SARS-CoV-2 infection. Vaccine effectiveness (VE) was calculated as (1 − adjusted odds ratio) × 100%.ResultsAmong 3847 participants included for analysis, 574 (32%) of 1775 tested positive for SARS-CoV-2 during the Delta predominant period and 1006 (56%) of 1794 participants tested positive during the Omicron predominant period. When Delta predominated, VE against symptomatic illness in outpatient settings was 63% (95% CI: 51% to 72%) among mRNA two-dose recipients and 96% (95% CI: 93% to 98%) for three-dose recipients. When Omicron predominated, VE was 21% (95% CI: −6% to 41%) among two-dose recipients and 62% (95% CI: 48% to 72%) among three-dose recipients.ConclusionsIn this adult population, three mRNA COVID-19 vaccine doses provided substantial protection against symptomatic illness in outpatient settings when the Omicron variant became the predominant cause of COVID-19 in the United States. These findings support the recommendation for a third mRNA COVID-19 vaccine dose. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | outpatient | |
dc.subject.other | COVID-19 | |
dc.subject.other | vaccine effectiveness | |
dc.title | Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021–February 2022 | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Microbiology and Immunology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175107/1/irv13029_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175107/2/irv13029.pdf | |
dc.identifier.doi | 10.1111/irv.13029 | |
dc.identifier.source | Influenza and Other Respiratory Viruses | |
dc.identifier.citedreference | Chung JR, Kim SS, Belongia EA, et al. Vaccine effectiveness against COVID-19 among symptomatic persons aged ≥12 years with reported contact with COVID-19 cases, February-September 2021. Influenza Other Respi Viruses. 2022; 16 ( 4 ): 673 - 679. doi: 10.1111/irv.12973 | |
dc.identifier.citedreference | Chung JR, Kim SS, Jackson ML, et al. Clinical symptoms among ambulatory patients tested for SARS-CoV-2. Open forum. Infect Dis. 2021; 8 ( 1 ): ofaa576. doi: 10.1093/ofid/ofaa576 | |
dc.identifier.citedreference | O’Toole Á, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus. Evolution. 2021 Sep 1; 7 ( 2 ): veab064. doi: 10.1093/ve/veab064 | |
dc.identifier.citedreference | Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013 Apr 19; 31 ( 17 ): 2165 - 2168. doi: 10.1016/j.vaccine.2013.02.053 | |
dc.identifier.citedreference | Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. N Engl J Med. 2022; 386 ( 19 ): 1804 - 1816. doi: 10.1056/NEJMoa2200797 | |
dc.identifier.citedreference | Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and Delta variants. Nat Med. 2022 Feb 21; 1 - 1. | |
dc.identifier.citedreference | Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and Delta variants. Jama. 2022 Feb 15; 327 ( 7 ): 639 - 651. doi: 10.1001/jama.2022.0470 | |
dc.identifier.citedreference | Centers for Disease Control and Prevention. COVID-19 ACIP vaccine recommendations. Accessed March 14, 2022. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html | |
dc.identifier.citedreference | Centers for Disease Control and Prevention. Science Brief: Omicron (B.1.1.529) Variant. Accessed March 14, 2022. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html | |
dc.identifier.citedreference | Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and omicron variant predominance - VISION network, 10 states, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022; 71 ( 4 ): 139 - 145. doi: 10.15585/mmwr.mm7104e3 | |
dc.identifier.citedreference | Tenforde MW, Patel MM, Gaglani M, et al. Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults - United States, august-December 2021. MMWR Morb Mortal Wkly Rep. 2022; 71 ( 4 ): 118 - 124. doi: 10.15585/mmwr.mm7104a2 | |
dc.identifier.citedreference | Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and omicron variant predominance - VISION network, 10 states, august 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022; 71 ( 7 ): 255 - 263. doi: 10.15585/mmwr.mm7107e2 | |
dc.identifier.citedreference | Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N Engl J Med. 2022; 386 ( 5 ): 492 - 494. doi: 10.1056/NEJMc2119358 | |
dc.identifier.citedreference | Flannery B, Meece JK, Williams JV, et al. Systematic testing for influenza and coronavirus disease 2019 among patients with respiratory illness. Clin Infect Dis. 2021; 72 ( 9 ): e426 - e428. doi: 10.1093/cid/ciaa1 | |
dc.identifier.citedreference | León TM, Dorabawila V, Nelson L, et al. COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis — California and New York, May–November 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 28; 71 ( 4 ): 125 - 131. doi: 10.15585/mmwr/mm7104e1 | |
dc.identifier.citedreference | Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the omicron variant from previous SARS-CoV-2 infection. N Engl J Med. 2022; 386 ( 13 ): 1288 - 1290. doi: 10.1056/NEJMc2200133 | |
dc.identifier.citedreference | Fisher KA, Tenforde MW, Feldstein LR, et al. Community and close contact exposures associated with COVID-19 among symptomatic adults ≥18 years in 11 outpatient health care facilities - United States, July 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 11; 69 ( 36 ): 1258 - 1264. doi: 10.15585/mmwr.mm6936a5 | |
dc.identifier.citedreference | Andrejko KL, Pry J, Myers JF, et al. Predictors of SARS-CoV-2 infection following high-risk exposure. Clin Infect Dis. 2021 Dec 21; ciab1040. doi: 10.1093/cid/ciab1040 | |
dc.identifier.citedreference | Tartof SY, Slezak JM, Puzniak L, et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study. The Lancet Regional Health - Americas. 2022 Feb 14; 100198. | |
dc.identifier.citedreference | Lewis NM, Naioti EA, Self WH, et al. Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March–August 2021. J Infect Dis. 2021; jiab619 doi: 10.1093/infdis/jiab619. | |
dc.identifier.citedreference | Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376: e069761. doi: 10.1136/bmj-2021-069761 | |
dc.identifier.citedreference | Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January–September 2021. MMWR Morb Mortal Wkly Rep. 2021; 70: 1553 – 1559. doi: 10.15585/mmwr.mm7044e3 | |
dc.identifier.citedreference | Bozio CH, Grannis SJ, Naleway AL, et al. Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September. MMWR Morb Mortal Wkly Rep. 2021; 2021 ( 44 ): 1539 - 1544. doi: 10.15585/mmwr.mm7044e1 | |
dc.identifier.citedreference | Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England. Nat Med. 2022; 28 ( 4 ): 831 - 837. doi: 10.1038/s41591-022-01699-1 | |
dc.identifier.citedreference | Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. Jama. 2021; 326 ( 20 ): 2043 - 2054. doi: 10.1001/jama.2021.19499 | |
dc.identifier.citedreference | Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022; 399 ( 10327 ): 814 - 823. doi: 10.1016/S0140-6736(22)00089-7 | |
dc.identifier.citedreference | Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022; 399 ( 10328 ): 924 - 944. doi: 10.1016/S0140-6736(22)00152-0 | |
dc.identifier.citedreference | Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022 Jan 27; 386 ( 4 ): 340 - 350. doi: 10.1056/NEJMoa2115481 | |
dc.identifier.citedreference | Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021; 385 ( 24 ): e85. doi: 10.1056/NEJMoa2114228 | |
dc.identifier.citedreference | Chemaitelly H, Tang P, Hasan MR. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021; 385 ( 24 ): e83. doi: 10.1056/NEJMoa2114114 | |
dc.identifier.citedreference | Abu-Raddad LJ, Chemaitelly H, Bertollini R. National study group for COVID-19 vaccination. Waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar. N Engl J Med. 2022; 386 ( 11 ): 1091 - 1093. doi: 10.1056/NEJMc2119432 | |
dc.identifier.citedreference | Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022; 386 ( 16 ): 1532 - 1546. doi: 10.1056/NEJMoa2119451 | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.